BRL Medicine Inc.

SUZHOU, China, Sept. 14, 2023 /PRNewswire/ -- On September 13th, 2023, Porton Advanced Solutions (Porton Advanced) announced a strategic partnership with BRL Medicine Inc. (BRL Medicine). This collaboration will enhance the cell and gene therapy pipelines from BRL Medicine from clinical trials to further expedite the commercialization of innovative therapies. Continue Reading Porton Advanced and BRL Medicine Build Strategic Partnership to Accelerate Commercialization of Gene and Cell Therapies BRL Medicine, with its strong gene editing technology, robust R&D capabilities, and prospective pipelines, has been devoted to the realm of CGT for years and has achieved significant progress. Multiple pipelines of the company have entered the IND application stage, with three core ones already receiving China IND approval. The gene therapy product, BRL-101, was developed using the in-house ModiHSC® hematopoietic stem cell platform. Whereas, the CAR-T product, BRL-201, was developed using the in-house non-viral site-specific integration CAR-T platform (Quikin CART®). Notably, both have shown impressive results in clinical trials, gaining recognition from prestigious international academic journals like Nature and Nature Medicine. Porton Advanced, on the other hand, has built an end-to-end gene and cell therapy CDMO service platform with proven experience in plasmids, cell therapy, gene therapy, oncolytic viruses, mRNA therapy, and bacterial therapy. Through this strategic partnership, the two companies will work together to accelerate the commercialization of gene and cell therapy drugs, making innovative treatments accessible to a wider range of patients. Dr. Zheng Biao, CEO of BRL Medicine, expressed his enthusiasm for the strategic collaboration with Porton Advanced, an international leader in the CGT field with a strong track record. BRL Medicine currently has three new drugs approved for China IND and is in the midst of rapid product commercialization, and high capacity demand. Dr. Zheng hopes that this diversified collaboration will expedite the clinical translation and implementation of multiple innovative drugs benefiting patients worldwide who suffer from genetic diseases, malignant tumors, and autoimmune disorders. Furthermore, he believes that this partnership will contribute to the flourishing development of China's pharmaceutical industry. Dr. Wang Yangzhou, CEO of Porton Advanced, also expressed his excitement about the profound partnership with BRL Medicine. Recognizing BRL Medicine's robust technological platform, sustained innovation capabilities, and remarkable results achieved in multiple R&D pipelines, Dr. Wang anticipates that Porton Advanced's end-to-end gene and cell therapy CDMO platform will support BRL Medicine in accelerating clinical trials and future commercial production of cell therapy products to introduce more innovative drugs that are safer, more effective, and more accessible. Dr. Wang hopes that through their joint efforts, they can contribute to the advancement of China's CGT field, ensuring the timely availability of quality drugs to the general public. About BRL Medicine At BRL Medicine Inc., we aim to become the world's leading Cellular & Gene pharmaceutical company in the era of new commercial civilization, with the mission of "Through innovation led by gene editing, develop breakthrough human therapeutics and benefit the whole world". With its independent R&D center and the "Shanghai Research Center for Gene Editing and Cell Therapy", jointly established by BRL Medicine and university, BRL Medicine has obtained more than 100 patent achievements, and initiated 5 Investigator-Initiated clinical Trials (IIT) in 8 leading hospitals in China, with many pipeline projects have entered into IND application stage. Among them, gene editing projects for β-thalassemia, PD1 knockout non-viral targeted integration CAR-T and UCART have achieved excellent clinical results and have published several academic papers in famous academic journals such as Nature, Nature Medicine and Nature biotechnology. BRL Medicine has built five technology platforms with independent intellectual property rights, including The Gene Editing Technology Innovation Platform, Hematopoietic Stem Cell Platform, The Quikin CAR-T Platform, Universal Cell Platform and Enhanced T Cell Platforms, and has a 7000 square meter GMP pilot plant and an operating team of nearly 200 people, which strongly guarantees the rapid transformation and application of innovative research. BRL Medicine continuously promotes rapid update and iteration of R&D products through patient needs and clinical feedback. Driven by the era of new commercial civilization, BRL Medicine holds an open, shared, and win-win attitude, and works with global innovative biomedical ecological chain companies to accelerate the transformation and implementation of innovative drugs, so as to benefit global patients with genetic diseases and malignant tumors! About Porton Advanced Porton Advanced is a subsidiary of the globally recognized CDMO Porton Pharma Solutions Ltd. (SZSE Stock Code 300363), founded in 2018. Located in Suzhou, China, Porton Advanced offers a cGMP-compliant manufacturing platform for plasmids, cell therapy, gene therapy, oncolytic virus, mRNA therapy, and bacterial therapy, enabling different development stages for global companies. Porton Advanced operates on a "Customer First" approach to Gene and Cell Therapeutics (GCT) manufacturing, anchored by its core principles of "Compliance, Expertise, and Open Collaboration". The company operates to rigorous, internationally harmonized Quality Management and IP protection standards, bringing innovative manufacturing solutions to the complex challenges in the GCT space. SOURCE Porton Advanced Solutions

SHANGHAI, May 31, 2022 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on bi-specific antibodies and other engineered bio-therapeutics for the treatment of cancer, inflammation, and other serious disorders, today announced that its Q-1802 clinical program was selected for presentation at American Society of Clinical Oncology (ASCO) Annual Meetings on June 3–7, 2022, and the abstract of relevant results for this study has been published on ASCO website ( ). The presentation will showcase the preliminary results of a first-in-human Phase 1a/1b, multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity Q-1802, a Claudin18.2/PD-L1 bi-specific therapeutic in patients with relapsed or refractory solid tumors after standard therapies. Professor Lin Shen from Peking University Cancer Hospital and Institute leads this study. The key data from the mono-therapy of Q-1802 in both dose-escalation and dose-expansion studies demonstrate excellent safety, tolerability, and preliminary anti-tumor activities of Q-1802 at the dose up to 10 mpk. The abstract for the study is found in 2022-ASCO-Annual –Meeting Abstracts (#2568), and the poster session information is listed below. First Author, Dr. Jifang Gong from the Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute will present the relevant results on Sunday, June 5, 2022. Session Title: Developmental Therapeutics—Immunotherapy Session Type: Poster Session Date: Sunday, June 5, 2022 Time: 8:00 AM - 11:00 AM, Chicago Time (CDT) Location: Hall A Abstract ID (Temp. ID): 2568 (368426) Poster Board #: 223 Role Responsibilities: Presenter Primary Track: Developmental Therapeutics—Immunotherapy Session begins on Jun 5, 2022 at 8:00 AM Chicago Time (CDT) Room: Hall A-14355 Persons: Dr. Jifang Gong Presenting from 8:00 AM - 11:00 AM, Chicago Time (CDT) About Q-1802 Q-1802, a humanized bi-specific antibody, is the first FDA-approved Claudin18.2/PD-L1 bi-specific therapeutic to enter clinical trial. In animal model studies, Q-1802 demonstrates both superior anti-tumor activities and excellent safety pro It recruits multiple immune mechanisms to kill tumor cells, offering a novel therapeutic opportunity for Claudin18.2 positive solid tumors. Q-1802 also exhibits robust physicochemical properties and superb productivity with titers exceeding 4 grams per liter. About QureBio Ltd. QureBio Ltd. is a clinical-stage biopharmaceutical company focusing on innovative biopharmaceuticals for urgent and unmet clinical needs, such as the treatment of refractory cancers, inflammation and other serious disorders. Founded by experienced scientists from the relevant fields, QureBio Ltd. has built up a series of proprietary technologies for engineered bio-macromolecules, including innovative platforms for bi-specific and tri-specific antibodies. Founded in 2017 with seed capital from Viva Bio-Innovator, QureBio Ltd. has since received a series of funds from Jundu Investment, Watson Capital, Shenzhen Capital Group, New value Capital, Bocom Industrial Investment (Hangzhou) Equity Investment Partnership, Suzhou Oriza Holdings, Hangzhou CAPITAL GuoShun, Zhuhai Longmen Capital Management, Shanghai Pudong Kechuang Group, Shenzhen Lihe Hongxin Venture and Three Rivers Capital. QureBio Ltd. has secured a Series-B funding of nearly 200 million CNY. QureBio Ltd. engages in collaboration with partners to develop novel therapeutics for unmet medical needs and has on-going cooperation with a series of industrial partners including BRL Medicine, BioMap, Precision Scientific, and Hengrui Pharmaceuticals, an industry leader in China.